Pathkey.AI (ASX: PKY) has secured its largest commercial contract to date, entering a Services Agreement with Imunexus Therapeutics for its TrialKey platform services.
The contract is valued at up to $100,000 plus GST, including an initial payment of $25,000 plus GST upon execution.
The remaining $75,000 plus GST is contingent on Imunexus Therapeutics completing future capital raisings.
With an initial term of one year, the agreement is structured in two sequential phases: Step 1 involves pilot/baseline work and future capital raising support, while Step 2 focuses on clinical alignment and protocol refinement.
TrialKey is designed for various use cases, including probability of success and risk assessment, early-phase trial design optimisation, pipeline benchmarking, and supporting investor communications and capital raising positioning.
Strategic Positioning and Recent Funding
Pathkey.AI has been strategically repositioning itself as an applied artificial intelligence company.
Its TrialKey platform remains central to this commercial strategy.
The company completed a $3.5 million capital raise in early February 2026, with the funds earmarked for supporting growth and the commercialisation of its TrialKey platform.
As of 30 January 2026, previous company disclosures indicated an estimated funding runway of approximately 1.35 quarters.
Governance and Operational Updates
The board of Pathkey.AI has been strengthened with key appointments, including Shannon Robinson as Non-Executive Chair and Paul Niardone as Non-Executive Director.
Recent filings highlight advancements in the TrialKey platform, particularly improvements in its Large Language Model (LLM)-based ingestion, curation, and structuring of clinical trial data.
The independent auditor's review of Pathkey.AI's half-year financial report for the period ended 31 December 2025 found no matters indicating non-compliance with the Corporations Act 2001 or AASB 134, affirming a true and fair view of the financial position.
Analyst View
Pathkey.AI's largest contract to date with Imunexus Therapeutics offers validation for its TrialKey platform, contributing to near-term revenue.
However, a substantial portion of the contract value is contingent on the counterparty's capital raising success, highlighting ongoing funding and execution risks.
The company's strategic pivot to applied AI, coupled with recent funding and governance updates, forms the broader context for this commercial development.
